psoriasis

Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion
Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion
Marketwatch
Valeant Pharmaceuticals
psoriasis
FDA
Duobrii
Flag link:
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
CP Wire
JNJ
NICE
Tremfya
psoriasis
Flag link:
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
JNJ
Tremfya
psoriasis
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
US approves UCB’s Cimzia for psoriasis
US approves UCB’s Cimzia for psoriasis
Pharma Times
FDA
UCB Pharma
Cimzia
psoriasis
Flag link:
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
CP Wire
AbbVie
EMA
Europe
risankizumab
psoriasis
Flag link:
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
AbbVie
psoriasis
risankizumab
Flag link:
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
CP Wire
UCB Pharma
CHMP
Cimzia
psoriasis
Flag link:
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
UCB Pharmaceuticals
Cimzia
psoriasis
Flag link:
Will Ilumya Kill Valeant's Psoriasis Dreams?
Will Ilumya Kill Valeant's Psoriasis Dreams?
Seeking Alpha
Sun Pharma
Ilumya
FDA
psoriasis
Siliq
Valeant Pharmaceuticals
Flag link:
Sun Pharma Receives Approval for New Plaque Psoriasis Drug
Sun Pharma Receives Approval for New Plaque Psoriasis Drug
CP Wire
Sun Pharma
psoriasis
Ilumya
FDA
Flag link:
An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D
An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D
Endpoints
immunotherapy
psoriasis
Escalier
R&D
Flag link:
Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis
Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis
Endpoints
Novartis
Cosentyx
psoriasis
Flag link:
Novartis goes 2-0 against J&J in psoriasis
Novartis goes 2-0 against J&J in psoriasis
Biopharma Dive
Novartis
JNJ
psoriasis
Cosentyx
Stelara
Flag link:
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Yahoo/Zacks.com
Novartis
psoriasis
Cosentyx
biosimilars
ankylosing spondylitis
Flag link:
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst
Fierce Pharma
AbbVie
psoriasis
risankizumab
JNJ
Tremfya
Flag link:
AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment
AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment
Marketwatch
AbbVie
psoriasis
risankizumab
clinical trials
Flag link:
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
Motley Fool
psoriasis
me-too drugs
Otezla
Celgene
Flag link:
AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition
AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition
Endpoints
AbbVie
psoriasis
risankizumab
Humira
Stelara
clinical trials
Flag link:
J&J psoriasis drug gets expanded U.S. approval for teens
J&J psoriasis drug gets expanded U.S. approval for teens
Yahoo/Reuters
JNJ
Stelara
psoriasis
FDA
Flag link:

Pages